Dr. Reddy’s completes Phase I study of proposed tocilizumab biosimilar Dr. Reddy’s is developing the proposed tocilizumab biosimilar as intravenous and subcutaneous formulations. Lupin intros generic PrezistaPrezista is a HIV-1 medicine used with Norvir (ritonavir) and other antiretroviral medicines to treat HIV-1 infection in adults. Mark Cuban Cost Plus Drug Company partners with Coherus to offer Humira biosimilar Mark Cuban Cost Plus Drug Company plans to offer Yusimry to its customers for $569.27, plus dispensing and shipping fees starting in July 2023. Alembic debuts generic Tarceva Erlotinib tablets are indicated for treating metastatic non-small cell lung cancer patients with tumors with specific growth factor mutations. Sandoz to move to permanent headquarters in central Basel in mid-2024 Sandoz expects to move from the Novartis Campus to its new headquarters in mid-2024. Lupin gains FDA OK for 2 generics The FDA has approved obeticholic acid tablets, 5 mg and 10 mg, which is a generic of Intercept’s Ocaliva. Fresenius Kabi launches generic Zemuron Rocuronium Bromide injection is part of Fresenius Kabi's +RFID portfolio of smart-labeled medications. Alvotech, Advanz Pharma to commercialize 5 proposed biosimilars in Europe The partnership agreement includes proposed biosimilars to Simponi, Entyvio and three additional early-stage undisclosed biosimilar candidates. Endo to distribute bivalirudin injection in ready-to-use vials Endo will commercialize the product through its Par sterile products business and expects to begin shipping in summer 2023. Celltrion USA obtains FDA nod for Humira biosimilar Yuflyma is FDA-approved to treat eight conditions, including Crohn’s disease and ulcerative colitis. First Previous 62 63 64 65 66 Next Last
